Ultragenyx Pharmaceutical (RARE) Goodwill (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Goodwill data on file, last reported at $44.0 million in Q1 2026.

• On a quarterly basis, Goodwill fell 0.91% year-over-year to $44.0 million in Q1 2026; TTM through Mar 2026 was $44.0 million, a 0.91% decrease from a year earlier, with the FY2025 full-year figure at $44.0 million, changed 0.0% from the prior year.
• Goodwill for Q1 2026 stood at $44.0 million, roughly flat from $44.0 million in the prior quarter.
• Over the last five years, Goodwill for RARE reached as high as $44.4 million in Q1 2022 and fell as low as $44.0 million in Q4 2024.
• Historically, Goodwill has averaged $44.3 million across 5 years, with a median of $44.4 million in 2022.
• Across the five-year window, Goodwill changed 0.0% in 2022 and slipped 0.91% in 2024, its largest moves.
• Year by year, Goodwill stood at $44.4 million in 2022, then changed by 0.0% to $44.4 million in 2023, then decreased by 0.91% to $44.0 million in 2024, then changed by 0.0% to $44.0 million in 2025, then changed by 0.0% to $44.0 million in 2026.
• Per Business Quant data, the three most recent Goodwill figures were $44.0 million in Q1 2026, $44.0 million in Q4 2025, and $44.4 million in Q3 2025.